Endpoint
Congenital cardiovascular malformation incidence (offspring)
CAT:outcome/congenital-cardiovascular-malformation-incidencereported in proportion1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| sertraline | up | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Reported to move it
1 finding
sertraline — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Pregnant women who used sertraline in the first trimester had a statistically significant increased risk of infant cardiovascular-related malformations (OR = 1.36; 95% CI = 1.06-1.74; I2 = 64.4%; n = 12) as well as atrial and/or ventricular septal defects (OR = 1.36, 95% CI = 1.06-1.76; I2 = 62.2%; n = 8).”
Quoted verbatim from Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies.. - Study
- meta-analysis
- Population
- Infants of pregnant women exposed to sertraline in the first trimester; meta-analysis of 12 cohort studies
Effect 1.36 odds ratio, 95% CI 1.06 to 1.74
Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies.2017PMID:27770542Permalink
How it is measured
Proportion of live-born infants with a diagnosed congenital cardiovascular malformation, including atrial or ventricular septal defects, ascertained by clinical diagnosis, birth-defect registry, or medical record review.
Sources cited
1 paper
- Subject
- congenital cardiovascular malformation incidence (offspring)
- Findings
- 1
- Papers
- 1